Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Deals
Biotech
Struggling Relmada pays $3M for Tourette’s asset from Asarina
After sharing plans to shutter last summer, Asarina Pharma has managed to sell off its Tourette syndrome candidate to Relmada Therapeutics.
Gabrielle Masson
Feb 7, 2025 11:00am
Acelyrin to be absorbed into Alumis in all-stock merger
Feb 7, 2025 5:35am
Affibody regains drug, says ex-ally unable to capitalize on data
Feb 3, 2025 5:18am
Kadimastem gets shareholder backing for NLS merger
Jan 31, 2025 9:42am
OS buys full IP rights to its lead drug, gains 2 more assets
Jan 29, 2025 10:30am
Takeda regains home rights to depression drug from Neurocrine
Jan 28, 2025 4:16am